The not-yet peer reviewed study led by Pfizer indicated the vaccine was effective in neutralizing virus with the so-called N501Y mutation of the spike protein.

Maria Van Kerkhove, WHO technical lead for COVID-19, said the mutated variant may be more transmissible, but there is no evidence it would increase the severity of the disease.